Zoetis Inc. (NYSE:ZTS) – Research analysts at Jefferies Group issued their Q3 2017 EPS estimates for Zoetis in a report issued on Thursday. Jefferies Group analyst J. Holford forecasts that the company will post earnings of $0.63 per share for the quarter. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.34 EPS, FY2018 earnings at $2.70 EPS, FY2019 earnings at $3.05 EPS, FY2020 earnings at $3.44 EPS and FY2021 earnings at $3.75 EPS.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the firm earned $0.49 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “Zoetis Inc. Forecasted to Post Q3 2017 Earnings of $0.63 Per Share (ZTS)” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/27/zoetis-inc-forecasted-to-post-q3-2017-earnings-of-0-63-per-share-zts.html.

A number of other equities research analysts have also recently commented on ZTS. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Cowen and Company set a $60.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday, July 11th. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price target (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price target on shares of Zoetis in a report on Friday, July 21st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $62.00 price target on shares of Zoetis in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $65.76.

Zoetis (NYSE ZTS) opened at 63.74 on Friday. The firm’s 50 day moving average is $64.54 and its 200 day moving average is $61.63. Zoetis has a 52-week low of $46.86 and a 52-week high of $66.35. The company has a market cap of $31.18 billion, a PE ratio of 36.03 and a beta of 1.02.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.66%. Zoetis’s payout ratio is presently 23.73%.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sii Investments Inc. WI raised its position in Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares during the period. Ironwood Investment Management LLC raised its position in Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Zoetis by 1.3% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the period. Wilbanks Smith & Thomas Asset Management LLC raised its position in Zoetis by 1.8% in the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock worth $354,000 after acquiring an additional 98 shares during the period. Finally, First Manhattan Co. raised its position in Zoetis by 1.1% in the second quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock worth $567,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 93.54% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.